Observational Study
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. May 15, 2025; 16(5): 101840
Published online May 15, 2025. doi: 10.4239/wjd.v16.i5.101840
Comparisons of various insulin resistance indices for new-onset metabolic syndrome before midlife: The CHIEF cohort study, 2014-2020
Wei-Nung Liu, Yi-Chiung Hsu, Yen-Po Lin, Kun-Zhe Tsai, Yen-Chen Lin, Pang-Yen Liu, Gen-Min Lin
Wei-Nung Liu, Pang-Yen Liu, Gen-Min Lin, Department of Medicine, Tri-Service General Hospital, Taipei 114, Taiwan
Yi-Chiung Hsu, Department of Biomedical Sciences and Engineering, Center for Astronautical Physics and Engineering, National Central University, Taoyuan 320, Taiwan
Yi-Chiung Hsu, Department of Medical Research, Cathay General Hospital, Taipei 106, Taiwan
Yen-Po Lin, Department of Critical Care Medicine, Taipei Tzu Chi General Hospital, New Taipei 23142, Taiwan
Kun-Zhe Tsai, Department of Stomatology of Periodontology, Mackay Memorial Hospital, Taipei 104, Taiwan
Yen-Chen Lin, Department of Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan 333, Taiwan
Gen-Min Lin, Department of Medicine, Hualien Armed Forces General Hospital, Hualien 970, Taiwan
Author contributions: Liu WN wrote and drafted the article; Lin YP collected the data; Tsai KZ analyzed the data; Hsu YC, Lin YC, and Liu PY reviewed the data, edited the manuscript, and made critical revisions related to important intellectual content; Lin GM contributed to conception and design of the study.
Supported by Medical Affairs Bureau Ministry of National Defense, No. MND-MAB-D-114222; and Hualien Armed Forces General Hospital, No. HAFGH-D-114008.
Institutional review board statement: The Institutional Review Board (IRB) of the Mennonite Christian Hospital (No. 16-05-008) in Hualien City of Taiwan approved access to the data for the CHIEF cohort study.
Informed consent statement: Written informed consent was obtained from all participants. The CHIEF cohort study was performed in accordance with the Good Clinical Practice Guidelines and the principles of the Declaration of Helsinki.
Conflict-of-interest statement: All authors declared to have no conflict of interest for this article.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Data sharing statement: The datasets generated and/or analyzed during the current study are not publicly available due to materials obtained from the military in Taiwan, which were confidential, but are available from the corresponding author on reasonable request.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Gen-Min Lin, MD, PhD, FACC, FAHA, FESC, Adjunct Associate Professor, Chief Doctor, Department of Medicine, Hualien Armed Forces General Hospital, No. 100 Jinfeng Street, Hualien 970, Taiwan. farmer507@yahoo.com.tw
Received: September 30, 2024
Revised: February 14, 2025
Accepted: March 6, 2025
Published online: May 15, 2025
Processing time: 209 Days and 2 Hours
Core Tip

Core Tip: This study examined the associations of various non-insulin-based insulin resistance (IR) indices with new-onset metabolic syndrome (MetS) in young military personnel. The greatest area under the receiver operating characteristic curve was found for the metabolic score for IR [METS-IR; 0.782; 95% confidence interval (CI): 0.762-0.801] (all P values compared to the other non-insulin-based IR indices < 0.05), followed by the triglyceride (TG)/high-density lipoprotein cholesterol (HDL-C) ratio (0.752; 95%CI: 0.731-0.772), the Zhejiang University index (0.743; 95%CI: 0.722-0.764), the TG glucose index (0.734; 95%CI: 0.713-0.756), the total cholesterol/HDL-C ratio (0.731; 95%CI: 0.709-0.752), and the alanine transaminase/aspartate transaminase ratio (0.734; 95%CI: 0.713-0.756). In conclusion, the METS-IR is the strongest predictor of new-onset MetS before midlife.